185 related articles for article (PubMed ID: 16621594)
1. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
Furesz J
Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
[TBL] [Abstract][Full Text] [Related]
2. Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV.
Bakker WA; Thomassen YE; van't Oever AG; Westdijk J; van Oijen MG; Sundermann LC; van't Veld P; Sleeman E; van Nimwegen FW; Hamidi A; Kersten GF; van den Heuvel N; Hendriks JT; van der Pol LA
Vaccine; 2011 Sep; 29(41):7188-96. PubMed ID: 21651934
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
4. New assays for the quality control of live oral poliovirus vaccine.
Furesz J; Levenbook I
Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
[TBL] [Abstract][Full Text] [Related]
5. Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP).
Alexander L; Birkhead G; Guerra F; Helms C; Hinman A; Katz S; LeBaron CW; Modlin J; Murphy TV; ;
Arch Pediatr Adolesc Med; 2004 Dec; 158(12):1106-12. PubMed ID: 15583093
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of post-polio certification immunization policies.
Sangrujee N; Cáceres VM; Cochi SL
Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
[TBL] [Abstract][Full Text] [Related]
7. Risk management in a polio-free world.
Bruce Aylward R; Sutter RW; Cochi SL; Thompson KM; Jafari H; Heymann D
Risk Anal; 2006 Dec; 26(6):1441-8. PubMed ID: 17184391
[TBL] [Abstract][Full Text] [Related]
8. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line.
Montagnon BJ
Dev Biol Stand; 1989; 70():27-47. PubMed ID: 2759353
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication.
Minor P
Vaccine; 2009 May; 27(20):2649-52. PubMed ID: 19428874
[TBL] [Abstract][Full Text] [Related]
10. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of alternative polio immunization policies in South Africa.
Griffiths UK; Botham L; Schoub BD
Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
[TBL] [Abstract][Full Text] [Related]
12. Poliovirus vaccine strains detected in stool specimens of immunodeficient children in South Africa.
Pavlov DN; Van Zyl WB; Kruger M; Blignaut L; Grabow WO; Ehlers MM
Diagn Microbiol Infect Dis; 2006 Jan; 54(1):23-30. PubMed ID: 16290028
[TBL] [Abstract][Full Text] [Related]
13. A case for developing antiviral drugs against polio.
Collett MS; Neyts J; Modlin JF
Antiviral Res; 2008 Sep; 79(3):179-87. PubMed ID: 18513807
[TBL] [Abstract][Full Text] [Related]
14. [Old and new prescriptions for infectious diseases and the newest recipes for biomedical products in plants].
Koprowski H
Arch Immunol Ther Exp (Warsz); 2002; 50(6):365-9. PubMed ID: 12549429
[TBL] [Abstract][Full Text] [Related]
15. Vaccines: quality issues.
Sokhey J; Sarkar S
J Indian Med Assoc; 2000 Jan; 98(1):22-3. PubMed ID: 11016141
[TBL] [Abstract][Full Text] [Related]
16. PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine.
Sanders BP; Edo-Matas D; Custers JH; Koldijk MH; Klaren V; Turk M; Luitjens A; Bakker WA; Uytdehaag F; Goudsmit J; Lewis JA; Schuitemaker H
Vaccine; 2013 Jan; 31(5):850-6. PubMed ID: 23123018
[TBL] [Abstract][Full Text] [Related]
17. Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria.
Korsun N; Kojouharova M; Vladimirova N; Fiore L; Litvinenko I; Buttinelli G; Fiore S; Voynova-Georgieva V; Mladenova Z; Georgieva D
J Med Virol; 2009 Sep; 81(9):1661-7. PubMed ID: 19626606
[TBL] [Abstract][Full Text] [Related]
18. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines.
Laassri M; Lottenbach K; Belshe R; Rennels M; Plotkin S; Chumakov K
J Infect Dis; 2006 May; 193(10):1344-9. PubMed ID: 16619180
[TBL] [Abstract][Full Text] [Related]
19. Present state and developments in the production of inactivated poliomyelitis vaccine.
van Wezel AL
Dev Biol Stand; 1981; 47():7-13. PubMed ID: 6262162
[TBL] [Abstract][Full Text] [Related]
20. Technology transfer of Sabin-IPV to new developing country markets.
Kreeftenberg H; van der Velden T; Kersten G; van der Heuvel N; de Bruijn M
Biologicals; 2006 Jun; 34(2):155-8. PubMed ID: 16650773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
